Shares of Retrophin surged Wednesday after announcing positive results for its drug that treats a rare kidney disease. In the Phase II study, patients responded to treatment at more than twice the rate of patients receiving a control drug. Retrophin will meet with the U.S. Food and Drug Administration to plan the critical Phase III study. Currently, there are no approved drugs for the rare disease, which causes scarring of the kidneys and leads to end-stage kidney disease.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
